$KTTA, $0.483. According to PennyGems App stock analysis the rebound in Pasithea shares draws attention to the next event on its clinical calendar. With a PAS-004 presentation scheduled for October 23, readers have a specific date and study to examine alongside the stock’s movement.
A dated clinical event is approaching
Pasithea scheduled a poster presentation of its Phase 1 PAS-004 dose-escalation study in patients with MAPK pathway-driven advanced solid tumors for October 23 at the ESMO Congress in Madrid. The scheduled session is 15:15–16:00 CEST, with poster number 1050P. [1]
The company announced the acceptance in July and lists the event on its investor calendar. This is an approaching event, not a newly announced successful trial result on October 21.
What the PennyGems captures add
The supplied KTTA chart shows 0.483, up 17.73%, with 752,983 shares traded and a GRAB label. Its six-month view also shows the decline preceding the rebound. The second screenshot shows the company profile and a six-month chart at 0.48, captured at a different moment.
Together, the two PennyGems images let readers compare the move and its context. Neither establishes what the upcoming presentation will report.
The scientific questions behind the calendar
The planned poster concerns safety and pharmacokinetics in an early-phase dose-escalation study. Readers should examine the number of patients, doses, follow-up and adverse-event reporting before interpreting any activity observations. [1]
PAS-004 is an investigational macrocyclic MEK inhibitor. A conference presentation offers information; it is not regulatory approval or proof that a treatment works across a broad population.
The article angle is anticipation versus evidence
A useful follow-up will compare the presented findings with prior disclosures and explain what has actually changed. Management’s stated next steps, development costs and trial progress also matter.
The event supplies a clear reason to research KTTA now. We have not independently established that anticipation of ESMO explains every part of the latest price gain.
Explore PennyGems
PennyGems helps organize stock research with charts, rating history, company information and industry portfolios. Explore the app for iPhone and Android through the links below. Its signals are research inputs, not guarantees of returns.
